Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Cancer Specialists Seek Fewer Restrictions On Medicare Coverage For PET

This article was originally published in The Gray Sheet

  • News

Executive Summary

Oncologists and imaging device manufacturers are urging CMS not to restrict coverage for PET scans used to detect recurrence, monitor treatment or restage a cancer prognosis after its initial diagnosis

You may also be interested in...



Oncology PET Scan Coverage Expands As CMS Lifts Some Data Mandates

Medicare coverage of PET scans for oncology indications will be less restrictive under a national coverage determination finalized April 3

Oncology PET Scan Coverage Expands As CMS Lifts Some Data Mandates

Medicare coverage of PET scans for oncology indications will be less restrictive under a national coverage determination finalized April 3

CMS Proposes To Require Less Data Collection For Cancer PET Coverage

CMS plans to remove some of its coverage-with-evidence-development (CED) requirements for positron emission tomography scans for an array of cancer types

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT027070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By